Navigation Links
Transgenomic, Inc. Presents Its Latest Technology at the BIT Life Sciences World DNA and Genome Day Conference, Dalian, China
Date:4/27/2011

OMAHA, Neb., April 27, 2011 /PRNewswire/ -- Transgenomic, Inc. (OTC/BB: TBIO) announced today that its President and Chief Executive Officer, Craig Tuttle, had presented the Company's latest results with its ultra-sensitive DNA mutation detection technology, COLD-PCR at BIT Life Sciences' 2nd World DNA and Genome Day Conference, April 25-30th, in Dalian, China. Nine Nobel Laureates were also giving presentations at this meeting.

US Congress designated April 25 as National DNA Day and the month April as Genome Month in celebration of the anniversary of James Watson and Francis Crick's publication of DNA Double Helix Structure.

"It is a great honor to be asked to present the latest developments of our cutting-edge technologies at such a prestigious event," commented Craig Tuttle, Transgenomic's Chief Executive Officer. The presentation was entitled "Ultra-sensitive DNA Mutation Detection: COLD-PCR Applied to Key Cancer Pathway Gene Mutations in Circulating Plasma DNA" and outlined Transgenomic's most recent findings in COLD-PCR assay development. "Our latest results with COLD-PCR demonstrate that we can detect mutations in free circulating tumor DNA in plasma or serum despite the presence of a high background of non-tumor derived wild-type DNA. We believe that this method promises to enable routine, non-invasive screening of plasma or serum samples for early detection of cancer or monitoring of post-treatment remission, relapse or emergence of resistance to therapy."

Tuttle also chaired the conference's session "Breaking Research in Genomics and Diseases."

About COLD-PCR

COLD-PCR is a genetic testing approach that selectively amplifies mutant DNA by recognizing that mutant DNA strands denature at lower temperatures in a PCR reaction than normal DNA. Using this proprietary technique, COLD-PCR amplifies mutated DNA with minimal amplification of the normal DNA. The resultant PCR-amplified fragment can be easily analyzed with a variety of sequencing approaches including Sanger sequencing, Pyrosequencing, real-time PCR or any next generation sequencing technology. Transgenomic has licensed rights to utilize any of these techniques. The enhanced analytic sensitivity of COLD-PCR allows clinicians to use smaller amounts of sample for their genetic analysis and less intrusive sample collection methods such as a blood draw for serum or plasma preparation, urine, fine needle aspirates or bronchial lavage as well as studying mutated DNA in tumors directly. The addition of the Ice COLD-PCR methodology further enhances the sensitivity.

About Transgenomic

Transgenomic, Inc. (www.transgenomic.com) is a global biotechnology company specializing in high sensitivity genetic variation and mutation analysis, providing products and services in DNA mutation detection and discovery for clinical research, clinical molecular diagnostics and pharmacogenomics analyses. Product offerings include the WAVE Systems and associated consumables specifically designed for use in genetic variation detection and single- and double-strand DNA/RNA analysis and purification. With broad applicability to genetic research, nearly 1,500 systems have been installed in customers' labs in more than 50 countries. The SURVEYOR Mutation Detection Kits provide reagents and protocols for high sensitivity detection of mutations in DNA. HANABI automated chromosome harvesting systems improve laboratory productivity with consistent quality compared with manual methods for cytogenetic karyotyping and FISH analyses. Transgenomic Pharmacogenomics Services is a CRO for pharmacogenomic, translational research and clinical trials. The Transgenomic Molecular Laboratories specialize in molecular diagnostics for cardiology, neurology, mitochondrial disorders, oncology, hematology, molecular pathology and other inherited diseases. Transgenomic believes there is a significant opportunity to continue growing the demand for its molecular-based testing by leveraging core technologies, experience, and expertise in biomarker analysis. In addition, the company continues to seek out and evaluate new technologies and new tests to extend its offerings in molecular diagnostics and pharmacogenomics services.

Forward-Looking Statements

Certain statements in this press release constitute "forward-looking statements" of Transgenomic within the meaning of the Private Securities Litigation Reform Act of 1995, which involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. Forward-looking statements include, but are not limited to, those with respect to management's current views and estimates of future economic circumstances, industry conditions, company performance and financial results, including the ability of the Company to grow its involvement in the diagnostic products and services markets. The known risks, uncertainties and other factors affecting these forward-looking statements are described from time to time in Transgenomic's filings with the Securities and Exchange Commission. Any change in such factors, risks and uncertainties may cause the actual results, events and performance to differ materially from those referred to in such statements. Accordingly, the Company claims the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995 with respect to all statements contained in this press release. All information in this press release is as of the date of the release and Transgenomic does not undertake any duty to update this information, including any forward-looking statements, unless required by law.

© 2011 Transgenomic, Inc. "TRANSGENOMIC," "WAVE" and "SURVEYOR" are registered trademarks of Transgenomic, Inc.


'/>"/>
SOURCE Transgenomic, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Transgenomic, Inc. Expands SURVEYOR® Scan Product Line With BRAF and PIK3CA Mutation Detection Kits
2. Transgenomic, Inc. Executes License Option agreement for Parkinsons Disease Diagnostic Markers with Gene Solutions, LLC
3. Reminder Webcast Alert: Transgenomic, Inc. Announces Third Quarter 2009 Earnings Release Conference Call Webcast
4. GE Healthcare Presents Interim Data on the Impact of DaTscan™ (Ioflupane I 123 Injection) SPECT Imaging on the Diagnosis and Clinical Management of Patients with Clinically Uncertain Parkinsonian Syndrome
5. Dr. Eva Feldman, Principal Investigator, Presents Interim Safety Results for Neuralstem ALS Trial
6. Cytotech Labs Unravels Hallmark Insight Into Metabolic Control of Cancer, Presents Work at Major AACR Cancer Meeting
7. Cardioxyl Pharmaceuticals Presents Data On Its Clinical Candidate, CXL-1020, at the 60th Annual American College of Cardiology Scientific Session
8. Regado Biosciences, Inc. Presents Results of the RADAR Phase 2b Clinical Trial of its REG1 Anticoagulation System
9. Conatus Pharmaceuticals Presents Results From a Phase 2 Clinical Trial of CTS-1027 in HCV Genotype 1 Null-Responders
10. ICAP Ocean Tomo Announces Four Patent Sets From Oxford Instruments - Each Represents an Important Advancement in Technology
11. NOVAVAX Presents Final Results from H1N1 Influenza Vaccine Trial at World Health Organization Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2017)... 2017  RXi Pharmaceuticals Corporation (NASDAQ: RXII), a ... significant unmet medical needs, today announced that it ... product development program, based on its proprietary self-delivering ... Dermatology (SID) 76 th Annual Meeting.  The ... sciences relevant to skin health and disease through ...
(Date:4/20/2017)... 20, 2017  AbbVie (NYSE: ABBV), a global ... of chronic hepatitis C virus (HCV) infected patients ... and compensated cirrhosis (Child-Pugh A) achieved sustained virologic ... with its investigational, pan-genotypic regimen of glecaprevir/pibrentasvir (G/P). ... following 12 weeks of G/P treatment without ribavirin. ...
(Date:4/20/2017)... -- Research and Markets has announced the addition ... Analysis By Service (Manufacturing, Research), By Country, (Brazil, Mexico, Colombia, ... report to their offering. ... The Latin American pharmaceutical contract manufacturing services market is ... Low drug registration cost in Latin American countries and continuous ...
Breaking Medicine Technology:
(Date:4/25/2017)... ... 25, 2017 , ... Somnoware, a leading provider of digital ... module. Using this new feature, sleep physicians can now predict the likelihood of ... airway pressure (CPAP), oral, or other forms of sleep apnea therapy. The Somnoware ...
(Date:4/25/2017)... ... April 25, 2017 , ... There is no better place in ... a special report in the May issue of Consumer Reports focused on heart health. ... for results achieved during and after coronary bypass and aortic valve replacement procedures. ...
(Date:4/25/2017)... (PRWEB) , ... April 25, 2017 , ... ... instrument solutions, announces the continuation of its strategic partnership with and platinum sponsorship ... developing nations in the safe and effective management of complex spine deformity cases, ...
(Date:4/24/2017)... ... April 24, 2017 , ... ... Bring Your Own Device (BYOD) capabilities at Telehealth 2.0, the American Telemedicine Association’s ... bundles, which pairs medical devices with a pre-programmed tablet in a remarkably easy-to-use ...
(Date:4/24/2017)... ... April 24, 2017 , ... The Santana Telehealth Project was honored with the ... the American Telemedicine Association’s annual conference, on April 23 in Orlando, FL. , “I ... improve the lives of the poor and underserved in other parts of the world,” ...
Breaking Medicine News(10 mins):